Copyright
©2014 Baishideng Publishing Group Inc.
World J Cardiol. Jun 26, 2014; 6(6): 434-443
Published online Jun 26, 2014. doi: 10.4330/wjc.v6.i6.434
Published online Jun 26, 2014. doi: 10.4330/wjc.v6.i6.434
Intervention | n | Outcome | |
Adenosine | |||
Mahaffey et al[59], 1999 (AMISTAD) | Infusion of adenosine for 3 h as adjunct to thrombolysis | 236 | Reduction in infarct size |
Kloner et al[60], 2006 (AMISTAD II) | Infusion of adenosine for 3 h | 2118 | No difference in death or heart failure |
Atrial natriuretic peptide | |||
Kitakaze et al[61], 2007 (J-WIND) | Infusion of atrial natriuretic peptide for 3 d | 569 | Reduction in creatine kinase, increase in LVEF |
Atorvastatin | |||
Kim et al[62], 2010 (STATIN-STEMI) | Oral atorvastatin 80 mg before primary PCI | 171 | No difference in death, revascularization or infarct size |
Hahn et al[63], 2011 | Oral atorvastatin 80 mg before primary PCI | 173 | No difference in infarct size |
Cyclosporine A | |||
Piot et al[64], 2008 | Infusion of cyclosporine before primary PCI | 58 | Reduction in infarct size |
Ghaffari et al[65], 2013 | Infusion of cyclosporine as adjunct to thrombolysis | 101 | No difference in infarct size, death, heart failure or LVEF |
Erythropoietin | |||
Voors et al[66], 2010 | Single dose erythropoietin | 529 | No difference in LVEF or infarct size |
Exenatide | |||
Lønborg et al[67], 2012 | Infusion of exenatide for 6 h | 105 | Reduction in infarct size |
Bernink et al[68], 2012 (EXAMI) | Loading dose of exenatide before PCI followed by infusion for 72 h | 39 | No difference in left ventricular function or infarct size |
Woo et al[69], 2013 | Subcutaneously and intravenous exenatide before primary PCI followed by twice daily subcutaneous injection for 2 d | 58 | Reduction in infarct size and improvement of LVEF |
Glucose-insulin-potassium | |||
Mehta et al[70], 2005 (CREATE-ECLA) | Infusion of glucose-insulin-potassium for 24 h | 20201 | No difference in mortality |
Selker et al[71], 2012 (IMMEDIATE) | Out-of-hospital infusion of GIK | 357 | Reduced mortality among patients with cardiac arrest |
δ-protein kinase C inhibitor | |||
Bates et al[72], 2008 | 2 doses of KAI-9803 | 154 | No difference in infarct size |
Lincoff et al 2012 (PROTECTION-AMI) | Infusion of delcasertib for 24 h | 1083 | No difference in infarct size |
P-selectin antagonist | |||
Mertens et al[73], 2006 (PSALM) | Infusion of recombinant P-selectin glycoprotein ligand-immunoglobulin as adjunct to thrombolysis | 88 | No difference in ST-segment resolution or LVEF |
Tardif et al[74], 2013 (SELECT-ACS) | Infusion of inclacumab before PCI in NSTEMI patients | 322 | Reduction in troponin I and creatine kinase |
Metoprolol | |||
Ibanez et al[75], 2013 (METOCARD-CNIC) | Infusion of metoprolol before primary PCI | 220 | Reduction in infarcts size and improvement of LVEF |
- Citation: Schmidt MR, Pryds K, Bøtker HE. Novel adjunctive treatments of myocardial infarction. World J Cardiol 2014; 6(6): 434-443
- URL: https://www.wjgnet.com/1949-8462/full/v6/i6/434.htm
- DOI: https://dx.doi.org/10.4330/wjc.v6.i6.434